A new Adtralza^® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc.

The single-use 2 mL pre-filled pen "simplifies the administration process with a hidden needle and press-down auto-injection mechanism and reduces the number of required injections, according to the press release. The product is indicated for patients aged 12 and older whose moderate-to-severe AD inadequately controlled with topical therapies or for whom these therapies are not advisable.

"The pre-filled pen simplifies the injection process and can be helpful for those who are uncomfortable with the sight of needles,” said Chih-ho Hong, MD, a dermatologist working in Greater Vancouver, BC, and national coordinating investigator for ECZTRA 6 trial in Canada, in the press release. “It also means half the number of required injections. This option can help reduce patient treatment burden significantly.”

Amanda Cresswell-Melville, Executive Director, Eczema Society of Canada, praised the expanded options for these patients.

“Atopic dermatitis can be difficult to manage, and can feel overwhelming,” she said. “More treatment options mean more hope to those impacted by this burdensome condition.”

Source: LEO Pharma Inc. press release. June 10, 2024.